Structured around the core concept of developing a new therapeutic pipeline to treat metabolic diseases that present global health challenges of patientsÂ’ unmet needs, Senseion Therapeutic is initially focused on advancing the firm's first-in-class drug candidate for the treatment of Nonalcoholic Steatohepatitis (NASH) - an advanced form of non-alcoholic fatty liver disease (NAFLD), in patients with Type 2 Diabetes. A primary arena of ongoing interest is SWELL1- controls multiple metabolic & vascular functions in vivo. Specific to Type 2 Diabetes, SWELL1 is a glucose sensor regulating ?-cell excitability and systemic glycaemia - effectively regulating insulin release and systemic glycemic control.
